Taken together, our study provides proof-of-principle that STAT3 inhibition using galiellalactone is a viable treatment option as monotherapy in ENZR prostate cancer as well as a logical strategy for combination therapy with ENZ in CRPC. The gene discussed is STAT3; the disease is prostate carcinoma.